Lumida
/PVLA
⌘K
Palvella Therapeutics Inc

Palvella Therapeutics Inc

PVLA
$157.24USD+6.41%+9.47 today

MARKET CAP

2.3B

P/E (TTM)

FWD P/E

DAY RANGE

$146 – $158

52W RANGE

$28
$161

AI Summary

Stalk
StalkMedium

Despite intact Stage 2 advancing structure and a secular uptrend, active Bullish Exhaustion and extreme overbought conditions suggest patience. The medium-term bias remains bullish, but execution should wait for a pullback into rising EMAs or support before engaging.

  • Phase III SELVA over-enrolled 51 vs 40 target, on track for 2H26 NDA
  • Q1 2026 cash of $261.9M post $230M financing funds operations into 2027
  • Negative earnings yield and weak profitability raise concerns on returns
Full analysis →
Insider Trades10 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 15, 2026SellPVLAKathleen GoinChief Operating Officer8,604$78.69$2.3B-2.57%+457.75%$677.1K+0.00%10b5-1Buy Now
Jun 17, 2026SellPVLAKathleen GoinChief Operating Officer8,604$59.42$2.3B-2.57%+457.75%$511.3K+0.00%10b5-1Buy Now
Jun 12, 2026BuyPVLAMatthew E KorenbergCFO, Treasurer1,000$13.60$2.3B-2.57%+457.75%$13.6K+0.60%Buy Now
May 20, 2026SellPVLAKathleen GoinChief Operating Officer8,604$59.33$2.3B-2.57%+457.75%$510.5K+0.00%10b5-1Buy Now
Apr 15, 2026SellPVLAKathleen GoinChief Operating Officer8,604$67.68$2.3B-2.57%+457.75%$582.3K+0.00%10b5-1Buy Now
Mar 18, 2026SellPVLAKathleen GoinChief Operating Officer8,604$63.05$2.3B-2.57%+457.75%$542.5K+0.00%10b5-1Buy Now
Feb 18, 2026SellPVLAKathleen GoinChief Operating Officer8,604$43.75$2.3B-2.57%+457.75%$376.4K+0.00%10b5-1Buy Now
Jan 21, 2026SellPVLAKathleen GoinChief Operating Officer8,604$52.87$2.3B-2.57%+457.75%$454.9K+0.00%10b5-1Buy Now
Dec 17, 2025SellPVLAKathleen GoinChief Operating Officer8,604$52.29$2.3B-2.57%+457.75%$449.9K+0.00%10b5-1Buy Now
Nov 19, 2025SellPVLAKathleen GoinChief Operating Officer8,604$47.17$2.3B-2.57%+457.75%$405.8K+0.00%10b5-1Buy Now